5 Tech Stocks to Buy Immediately
Eric Fry, one of America's top Investment Strategists, provides his latest report 5 Top Stocks for 2022.

You can't afford to miss out on the once in a decade chance to buy after the recent dip in the markets.
Download this hot-off-the-presses research report now. It’s yours FREE.
Bradley L. Campbell, insider at Amicus Therapeutics
Bradley L. Campbell Insider Alerts

Get notified the next time Bradley L. Campbell buys or sells Amicus Therapeutics stock. Enter your email address below to get our daily insider buying and selling report.

Bradley L. Campbell Insider Information

Bradley L. Campbell is the President and Chief Operating Officer of Amicus Therapeutics and is also a member of the Board of Directors. He brings nearly 20 years of experience in the Orphan Drug industry. Mr. Campbell joined Amicus in 2006 and leads the global organization responsible for the commercialization of Galafold®. He also oversees the Technical Operations, Market Access, Program Management, Clinical Operations and Regulatory Affairs functions

Mr. Campbell currently serves on a number of Boards including ARYA Sciences Acquisition Corp III, a healthcare focused Special Purpose Acquisition Vehicle formed by Perceptive Advisors, the Association for Regenerative Medicine (ARM), and the Corporate Advisory Board for the National Tay-Sachs and Allied Diseases Association. He previously served on the Board of Progenics Pharmaceuticals from 2016 until its successful acquisition by Lantheus Holdings in 2020.

Prior to Amicus, Mr. Campbell spent time in various commercial and business development roles at Genzyme and Bristol-Myers Squibb and as a strategy consultant for Marakon Associates. He received a B.A. in Public Policy from Duke University and an M.B.A. from Harvard Business School.

What is Bradley L. Campbell's net worth?

The estimated net worth of Bradley L. Campbell is at least $3.89 million as of May 3rd, 2021. Mr. Campbell owns 422,536 shares of Amicus Therapeutics stock worth more than $3,891,557 as of January 20th. This net worth evaluation does not reflect any other investments that Mr. Campbell may own. Learn More.

What is Bradley L. Campbell's salary?

As the COO of Amicus Therapeutics, Inc., Mr. Campbell earned a total compensation package of $4,638,818.00 in 2020. Mr. Campbell earned a salary of $515,789.00, a bonus of $368,872.00, stock awards of $2,557,304.00, options awards of $1,163,159.00, and other compensation of $33,694.00.

How do I contact Bradley L. Campbell?

The corporate mailing address for Mr. Campbell and other Amicus Therapeutics executives is 1 Cedar Brook Drive, Cranbury NJ, 08512. Amicus Therapeutics can also be reached via phone at (215) 921-7600 and via email at [email protected]

Has Bradley L. Campbell been buying or selling shares of Amicus Therapeutics?

Bradley L. Campbell has not been actively trading shares of Amicus Therapeutics in the last ninety days. Most recently, Bradley L. Campbell sold 10,514 shares of the business's stock in a transaction on Monday, May 3rd. The shares were sold at an average price of $10.27, for a transaction totalling $107,978.78. Following the completion of the sale, the chief operating officer now directly owns 422,536 shares of the company's stock, valued at $4,339,444.72.

Who are Amicus Therapeutics' active insiders?

Amicus Therapeutics' insider roster includes Lynn Bleil (Director), Bradley Campbell (COO), Bradley Campbell (COO), John Crowley (CEO), John Crowley (CEO), Margaret Mcglynn (Director), Samantha Prout (Insider), and Burke Whitman (Director).

Are insiders buying or selling shares of Amicus Therapeutics?

During the last year, Amicus Therapeutics insiders bought shares 8 times. They purchased a total of 39,105 shares worth more than $354,377.70. During the last year, insiders at the biopharmaceutical company sold shares 35 times. They sold a total of 569,658 shares worth more than $6,693,258.28. The most recent insider tranaction occured on January, 18th when CEO John F Crowley sold 8,564 shares worth more than $87,609.72. Insiders at Amicus Therapeutics own 2.5 % of the company.

Information on this page was last updated on 1/18/2022.

Bradley L. Campbell Insider Trading History at Amicus Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/3/2021Sell10,514$10.27$107,978.78422,536View SEC Filing Icon  
9/21/2015Sell13,001$16.78$218,156.78156,575View SEC Filing Icon  
See Full Table

Bradley L. Campbell Buying and Selling Activity at Amicus Therapeutics

This chart shows Bradley L. Campbell's buying and selling at Amicus Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Amicus Therapeutics Company Overview

Amicus Therapeutics logo
Amicus Therapeutics, Inc. operates as a biotechnology company. The firm focuses on discovering, developing and delivering medicines for people living with metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio. The company was founded by John Francis Crowley on February 4, 2002 and is headquartered in Philadelphia, PA.
Read More

Today's Range

Now: $9.21
Low: $9.18
High: $9.91

50 Day Range

MA: $11.04
Low: $9.21
High: $12.48

2 Week Range

Now: $9.21
Low: $8.40
High: $21.34

Volume

2,238,868 shs

Average Volume

4,022,053 shs

Market Capitalization

$2.57 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.21
1,000X Bigger than Crypto? ($25 Gets You In) 
LIVE ON CAMERA: The man who called #1 tech stocks of 2016, 2018, 2019 & 2020 based on return…

Reveals the details of a new tech set to grow: 113X bigger than the Internet… 600X bigger than 5G… 2,000X BIGGER than Bitcoin… "This is the biggest investing moment in 400 years — and just $25 gets you in."

Brown believes the rollout could be days away...
Watch Jeff's presentation HERE before it's too late.